These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 8315572)

  • 21. Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys.
    Hart MK; Palker TJ; Matthews TJ; Langlois AJ; Lerche NW; Martin ME; Scearce RM; McDanal C; Bolognesi DP; Haynes BF
    J Immunol; 1990 Oct; 145(8):2677-85. PubMed ID: 1698859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1 proteins in infected cells determine the presentation of viral peptides by HLA class I and class II molecules and the nature of the cellular and humoral antiviral immune responses--a review.
    Becker Y
    Virus Genes; 1994 Jul; 8(3):249-70. PubMed ID: 7975271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunization of chimpanzees with recombinant gp160, but not infection with human immunodeficiency virus type 1, induces envelope-specific Th1 memory cells.
    Mannhalter JW; Fischer MB; Wolf HM; Küpcü Z; Barrett N; Dorner F; Eder G; Eibl MM
    J Infect Dis; 1995 Feb; 171(2):437-40. PubMed ID: 7844384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.
    Kovacs JA; Vasudevachari MB; Easter M; Davey RT; Falloon J; Polis MA; Metcalf JA; Salzman N; Baseler M; Smith GE
    J Clin Invest; 1993 Aug; 92(2):919-28. PubMed ID: 7688766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    Gorse GJ; Corey L; Patel GB; Mandava M; Hsieh RH; Matthews TJ; Walker MC; McElrath MJ; Berman PW; Eibl MM; Belshe RB
    AIDS Res Hum Retroviruses; 1999 Jan; 15(2):115-32. PubMed ID: 10029244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Production of long-lived neutralizing antibodies to HIV-1 IIIB in mice with a vaccinia recombinant virus-infected cell vaccine expressing gp160.
    Parry C; McLain L; Dimmock NJ
    AIDS Res Hum Retroviruses; 1994 Feb; 10(2):205-12. PubMed ID: 8198873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
    J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lymphoproliferative responses to mitogens and HIV-1 envelope glycoprotein among volunteers vaccinated with recombinant gp160.
    Tacket CO; Baqar S; Munoz C; Murphy JR
    AIDS Res Hum Retroviruses; 1990 Apr; 6(4):535-42. PubMed ID: 2187503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunization of mice with human immunodeficiency virus glycoprotein gp160 peptide 315-329 induces both class I- and class II-restricted T cells: not all T cells can respond to whole molecule stimulation.
    Moore RL; Fox BS
    AIDS Res Hum Retroviruses; 1993 Jan; 9(1):51-9. PubMed ID: 7678972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of synthetic peptides corresponding to various epitopes of the human immunodeficiency virus envelope protein.
    Zaghouani H; Hall B; Shah H; Bona C
    Adv Exp Med Biol; 1991; 303():53-62. PubMed ID: 1725238
    [No Abstract]   [Full Text] [Related]  

  • 31. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
    Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
    Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC; Graham BS; Kliks S; Wright PF
    J Clin Immunol; 1992 Nov; 12(6):429-39. PubMed ID: 1287035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
    Li Y; Svehla K; Mathy NL; Voss G; Mascola JR; Wyatt R
    J Virol; 2006 Feb; 80(3):1414-26. PubMed ID: 16415019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160. The NIAID AIDS Vaccine Clinical Trials Network.
    Gorse GJ; Belshe RB; Newman FK; Frey SE
    Vaccine; 1992; 10(6):383-8. PubMed ID: 1534641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV experimental vaccines based on the iscom technology using envelope and GAG gene products.
    Akerblom L; Nara P; Dunlop N; Putney S; Morein B
    Biotechnol Ther; 1993; 4(3-4):145-61. PubMed ID: 8292967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of humoral and cellular immune responses in mice induced by immunization with HIV-1 Nef regulatory protein encapsulated in poly(DL-lactide-co-glycolide) microparticles.
    Moureau C; Vidal PL; Bennasser Y; Moynier M; Nicaise Y; Aussillous M; Barthelemy S; Montagnier L; Bahraoui E
    Mol Immunol; 2002 Jan; 38(8):607-18. PubMed ID: 11792429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.
    VanCott TC; Mascola JR; Kaminski RW; Kalyanaraman V; Hallberg PL; Burnett PR; Ulrich JT; Rechtman DJ; Birx DL
    J Virol; 1997 Jun; 71(6):4319-30. PubMed ID: 9151820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cross-neutralizing antibodies in rabbits immunized with HIV-1 gp160 purified from simian cells infected with a recombinant vaccinia virus.
    Klaniecki J; Dykers T; Travis B; Schmitt R; Wain M; Watson A; Sridhar P; McClure J; Morein B; Ulrich JT
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):791-8. PubMed ID: 1742074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of humoral and cellular immune responses to the human immunodeficiency type 1 virus in nonhuman primates by in vivo DNA inoculation.
    Wang B; Boyer J; Srikantan V; Ugen K; Gilbert L; Phan C; Dang K; Merva M; Agadjanyan MG; Newman M
    Virology; 1995 Aug; 211(1):102-12. PubMed ID: 7645204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of neutralizing antibodies against human immunodeficiency virus type 1 using synthetic peptide constructs containing an immunodominant T-helper cell determinant from vpr.
    Sarobe P; Lasarte JJ; Golvano JJ; Prieto I; Gullón A; Soto MJ; Labarga P; Prieto J; Borrás-Cuesta F
    J Acquir Immune Defic Syndr (1988); 1994 Jul; 7(7):635-40. PubMed ID: 8207641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.